$HEM grants worldwide field license to PreCerv Inc.
Hemostemix recently granted the global field license of use of NCP-01 and its autologous stem cell therapies to PreCerv Inc. its wholly owned subsidiary to aid patients with peripheral and central nervous system conditions
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.